Literature DB >> 11547544

Anti-cancer activities of hypericin in the dark.

M Blank1, M Mandel, S Hazan, Y Keisari, G Lavie.   

Abstract

The potent photodynamic properties of hypericin (HY) elicit a range of light-dependent virucidal and tumoricidal activities. Yet, a relatively low reduction/oxidation potential endows HY with electron accepting and donating properties enabling it to act as both an oxidizing and a reducing agent. HY can thus compete as an electron acceptor from bioenergized reduction/oxidation reactions generating its excitation energy for biological activities from physiological reduction/oxidation reactions in the absence of light. Our studies show that HY can inhibit the growth of highly metastatic murine breast adenocarcinoma and squamous cell carcinoma tumors in culture. Furthermore, we show that HY can interfere with the growth of these tumors in mice reducing tumor size and prolonging animal survival in complete absence of light. While there is no evidence that HY induces apoptosis in these cells in the dark, 3H-thymidine incorporation into DNA was significantly reduced indicating effects that are apparently cytostatic in nature compared to the cytocidal effects of HY with light.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11547544     DOI: 10.1562/0031-8655(2001)074<0120:acaohi>2.0.co;2

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  9 in total

1.  Characterizing the metabolic fingerprint and anti-inflammatory activity of Hypericum gentianoides.

Authors:  Matthew L Hillwig; Kimberly D P Hammer; Diane F Birt; Eve Syrkin Wurtele
Journal:  J Agric Food Chem       Date:  2008-05-31       Impact factor: 5.279

Review 2.  An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.

Authors:  Marlein Miranda Cona; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  World J Methodol       Date:  2013-12-26

3.  Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model.

Authors:  Chad D Cole; James K Liu; Xiaoming Sheng; Steven S Chin; Meic H Schmidt; Martin H Weiss; William T Couldwell
Journal:  J Neurooncol       Date:  2008-01-29       Impact factor: 4.130

4.  Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.

Authors:  Tilda Barliya; Mathilda Mandel; Tami Livnat; Dov Weinberger; Gad Lavie
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

Review 5.  Applications of SNAP-tag technology in skin cancer therapy.

Authors:  Eden Rebecca Padayachee; Henry Ademola Adeola; Jennifer Catherine Van Wyk; Fleury Augustine Nsole Biteghe; Shivan Chetty; Nonhlanhla Patience Khumalo; Stefan Barth
Journal:  Health Sci Rep       Date:  2019-01-08

6.  Novel Insights into the Effect of Hyperforin and Photodynamic Therapy with Hypericin on Chosen Angiogenic Factors in Colorectal Micro-Tumors Created on Chorioallantoic Membrane.

Authors:  Martin Majerník; Rastislav Jendželovský; Marián Babinčák; Ján Košuth; Juraj Ševc; Zuzana Tonelli Gombalová; Zuzana Jendželovská; Monika Buríková; Peter Fedoročko
Journal:  Int J Mol Sci       Date:  2019-06-19       Impact factor: 5.923

7.  Hypericin, a potential new BH3 mimetic.

Authors:  Anastasia Doroshenko; Silvia Tomkova; Tibor Kozar; Katarina Stroffekova
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

8.  In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Authors:  Rainer Ritz; Christian Scheidle; Susan Noell; Florian Roser; Martin Schenk; Klaus Dietz; Wolfgang S L Strauss
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

Review 9.  Hypericin in the Light and in the Dark: Two Sides of the Same Coin.

Authors:  Zuzana Jendželovská; Rastislav Jendželovský; Barbora Kuchárová; Peter Fedoročko
Journal:  Front Plant Sci       Date:  2016-05-06       Impact factor: 5.753

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.